The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial
Open accessAbstract
BACKGROUND: Relentless chronic pulmonary inflammation is the major contributor to morbidity and mortality in patients with cystic fibrosis (CF). While immunomodulating therapies such as prednisolone and ibuprofen may be beneficial, their use is limited by side effects. Macrolides have immunomodulatory properties and long term use dramatically improves prognosis in diffuse panbronchiolitis, a condition with features in common with the lung disease of CF. METHODS: To determine if azithromycin (AZM) improves clinical parameters and reduces inflammation in patients with CF, a 3 month prospective randomised double blind, placebo controlled study of AZM (250 mg/day) was undertaken in adults with CF. Monthly assessment included lung function, weight, and quality of life (QOL). Blood and sputum collection assessed systemic inflammation and changes in bacterial flora. Respiratory exacerbations were treated according to the policy of the CF Unit. RESULTS: Sixty patients were recruited (29 men) of mean (SD) age 27.9 (6.5) years and initial forced expiratory volume in 1 second (FEV1) 56.6 (22.3)% predicted. FEV1% and forced vital capacity (FVC)% predicted were maintained in the AZM group while in the placebo group there was a mean (SE) decline of -3.62 (1.78)% (p=0.047) and -5.73 (1.66)% (p=0.001), respectively. Fewer courses of intravenous antibiotics were used in patients on AZM (0.37 v 1.13, p=0.016). Median C reactive protein (CRP) levels declined in the AZM group from 10 to 5.4 mg/ml but remained constant in the placebo group (p<0.001). QOL improved over time in patients on AZM and remained unchanged in those on placebo (p=0.035). CONCLUSION: AZM in adults with CF significantly improved QOL, reduced CRP levels and the number of respiratory exacerbations, and reduced the rate of decline in lung function. Long term AZM may have a significant impact on morbidity and mortality in patients with CF. Further studies are required to define frequency of dosing and duration of benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A measure of quality of life for clinical trials in chronic lung disease
Guyatt, G. H., Berman, L. B., Townsend, M., Pugsley, S. O., & Chambers, L. W. (1987) · Thorax · doi:10.1136/thx.42.10.773 · Cited by 1,721
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
Ramsey, B. W., Pepe, M. S., Quan, J. M., Otto, K. L., Montgomery, A. B., Williams-Warren, J., Vasiljev-K, M., Borowitz, D., Bowman, C. M., Marshall, B. C., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400104 · Cited by 1,300
Long-term azithromycin may improve lung function in children with cystic fibrosis
Jaffé, A., Francis, J., Rosenthal, M., & Bush, A. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78360-4 · Cited by 276
Erythromycin Modulates IL-8 Expression in Normal and Inflamed Human Bronchial Epithelial Cells
TAKIZAWA, H., DESAKI, M., OHTOSHI, T., KAWASAKI, S., KOHYAMA, T., SATO, M., TANAKA, M., KASAMA, T., KOBAYASHI, K., NAKAJIMA, J., et al. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.156.1.9612065 · Cited by 233
Modulatory effect of antibiotics on cytokine production by human monocytes in vitro
Morikawa, K., Watabe, H., Araake, M., & Morikawa, S. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.6.1366 · Cited by 211
Treatment compliance in adults with cystic fibrosis.
Abbott, J., Dodd, M., Bilton, D., & Webb, A. K. (1994) · Thorax · doi:10.1136/thx.49.2.115 · Cited by 188
Compliance with treatment in adult patients with cystic fibrosis.
Conway, S. P., Pond, M. N., Hamnett, T., & Watson, A. (1996) · Thorax · doi:10.1136/thx.51.1.29 · Cited by 182
Effect of clarithromycin and azithromycin on production of cytokines by human monocytes
Khan, A., Slifer, T., Araujo, F., & Remington, J. (1999) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(98)00091-0 · Cited by 167
Desaki, M., Takizawa, H., Ohtoshi, T., Kasama, T., Kobayashi, K., Sunazuka, T., Omura, S., Yamamoto, K., & Ito, K. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1917 · Cited by 164
Abe, S., Nakamura, H., Inoue, S., Takeda, H., Saito, H., Kato, S., Mukaida, N., Matsushima, K., & Tomoike, H. (2000) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.22.1.3400 · Cited by 142
Wolter, J. M., Bowler, S., Nolan, P., & McCormack, J. G. (1997) · European Respiratory Journal · doi:10.1183/09031936.97.10040896 · Cited by 138
Self-citationKawamura‐Sato, K., Iinuma, Y., Hasegawa, T., Horii, T., Yamashino, T., & Ohta, M. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2869-2872.2000 · Cited by 95
Oldfield, E. C., Fessel, W. J., Dunne, M. W., Dickinson, G., Wallace, M. R., Byrne, W. R., Chung, R. T., Wagner, K. F., Paparello, S. F., Craig, D. B., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/514566 · Cited by 85
Macrolides for the treatment of Pseudomonas aeruginosa infections?
Howe, R. A. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.2.153 · Cited by 61
Clinical relevance of intracellular and extracellular concentrations of macrolides
Carbon, C. (1995) · Infection · doi:10.1007/bf02464953 · Cited by 40
Bradley, J. M., Dempster, M., Wallace, E. S., & Elborn, J. S. (1999) · Quality of Life Research · doi:10.1023/a:1026437214170 · Cited by 26
Cited by
European Position Paper on Rhinosinusitis and Nasal Polyps 2020
Fokkens, W. J., Lund, V. J., Hopkins, C., Hellings, P. W., Kern, R., Reitsma, S., Toppila-Salmi, S., Bernal-Sprekelsen, M., Mullol, J., Alobid, I., et al. (2020) · Rhinology journal · doi:10.4193/rhin20.600 · Cited by 5,882
Antibiotic resistance of bacterial biofilms
Høiby, N., Bjarnsholt, T., Givskov, M., Molin, S., & Ciofu, O. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.12.011 · Cited by 3,225
Fokkens, W. J., Lund, V. J., Mullol, J., Bachert, C., Alobid, I., Baroody, F., Cohen, N., Cervin, A., Douglas, R., Gevaert, P., et al. (2012) · Rhinology journal · doi:10.4193/rhino12.000 · Cited by 2,387
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Gibson, R. L., Burns, J. L., & Ramsey, B. W. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200304-505so · Cited by 1,633
O'Sullivan, B. P., & Freedman, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60327-5 · Cited by 1,320
Metadata
- Authors
- Wolter, J.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2002-03-01
- Volume
- 57
- Issue
- 3
- Pages
- 212-216
- ISSN
- 0040-6376 (ISSN-L)
- OpenAlex
- W2123178771
- Cited by
- 518
- References
- 16
- FWCI
- 32.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.